Statistical Issues in Drug Research and Development

Karl E. Peace (Georgia Southern University, Statesboro, USA)

$94.99

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

CRC Press
30 June 2020

Clinical trials; Probability & statistics; Biology, life sciences; Pharmaceutical technology

Series: Statistics: A Series of Textbooks and Monographs

This book is a compilation of topics addressed by the ASA Biopharmaceutical Section work groups, including the etiology and evolution of the work groups, the work group guidelines and structure, and the statistical issues associated with clinical trials in clinical drug development programs.

Edited by: Karl E. Peace (Georgia Southern University Statesboro USA)
Imprint: CRC Press
Country of Publication: United Kingdom
Dimensions: Height: 229mm, Width: 152mm,
Weight: 526g
ISBN: 9780367580179
ISBN 10: 0367580179
Series: Statistics: A Series of Textbooks and Monographs
Pages: 384
Publication Date: 30 June 2020
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Active

1. ASA Biopharmaceutical Section Work Groups 2. Summarization, Analysis, and Monitoring of Adverse Experiences 3. Two Treatment Crossover Designs 4. Active Control Equivalence Studies 5. Optimization in Clinical Trials and Combination Drug Development 6. Dosing in the Elderly 7. Intention to Treat in Clinical Trials 8. Dual Control Groups in Rodent Carcinogenicity Studies

Karl E. Peace